Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...
Life Molecular Imaging (LMI), an international pharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging, announces that the U.S. Food and ...
CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human ...
In a report released yesterday, Faisal Khurshid from Leerink Partners maintained a Buy rating on Trevi Therapeutics (TRVI – Research Report), ...
The drug has been granted Breakthrough Therapy designation by the FDA for the treatment of chronic hepatitis delta (CHD).
Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 ...
The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the ...
Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 -WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, ...
For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.
SAN DIEGO - Inhibrx Biosciences, Inc. (NASDAQ: INBX), a clinical-stage biopharmaceutical company valued at $195 million, ...